Actively Recruiting
A Retrospective Analysis of Tranexamic Acid Use Trends in Cesarean Deliveries with Postpartum Hemorrhage
Led by Mahidol University · Updated on 2025-12-22
648
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Postpartum hemorrhage (PPH) is a leading cause of maternal death worldwide, especially in Thailand where it accounts for 20-30% of maternal fatalities. The World Maternal Antifibrinolytic Trial (WOMAN Trial) in 2017 showed that giving tranexamic acid (TXA) within three hours of bleeding onset reduces PPH-related deaths by 31%. Following this, the World Health Organization updated its guidelines to recommend TXA as part of standard care for all PPH cases. This study aims to analyze the recent increase in TXA use and its effects on outcomes during cesarean deliveries complicated by PPH. This observational study compares patients who received tranexamic acid after PPH with those who did not, focusing on those undergoing cesarean delivery. The study examines trends in TXA use over time following WHO recommendations and evaluates related obstetric and perinatal outcomes. The treatments are not assigned but observed retrospectively to assess the impact of TXA administration in real-world clinical practice. Participants' medical records will be reviewed to collect data on TXA administration rates within 24 hours after delivery, amount of blood loss, blood transfusions, additional interventions, reoperations, causes of PPH, side effects, hospital stay length, and maternal mortality up to 30 days postpartum. The study updates previous findings by analyzing these outcomes in relation to the increased use of TXA after 2017. The total participation involves retrospective data collection from cesarean deliveries complicated by PPH.
CONDITIONS
Brief Title
Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who underwent cesarean delivery with primary postpartum hemorrhage
You will not qualify if you...
- Gestational age less than 24 weeks
- Missing anesthetic record
- Received tranexamic acid during the antepartum period
- Blood loss less than 1,000 ml
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 24 hours after delivery
Participants who underwent cesarean delivery with postpartum hemorrhage are observed to analyze the use of tranexamic acid and related outcomes.
1 visit (in-person) during hospital stay
Duration - After delivery to 30 days
Participants are monitored for side effects of tranexamic acid administration, hospital length of stay, and maternal mortality after delivery.
Follow-up visits or assessments during the 30 days after delivery
Trial Site Locations
Total: 1 location
1
Siriraj Hospital
Bangkoknoi, Bangkok, Thailand, 10700
Actively Recruiting
Research Team
P
Patchareya Nivatpumin, M.D.
P
Premyuda Matangkarat, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here